erlotinib, gemcitabine, and vinorelbine

The combination of erlotinib, gemcitabine, and vinorelbine is a chemotherapy regimen that has been studied for the treatment of non-small cell lung cancer (NSCLC). This specific three-drug combination doesn't appear to have extensive clinical data in the search results, and there isn't clear evidence supporting its efficacy for NSCLC or other cancers based on the provided information. It consists of erlotinib (an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor), gemcitabine (a chemotherapeutic agent commonly used in combination regimens), and vinorelbine (an anti-mitotic chemotherapy drug that works by interfering with tubulin polymerization and inhibiting mitosis at metaphase).